2-氨基噻吩-3-甲酸乙酯 | 31891-06-2

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 酯类氨基酸
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 中文名称: 2-氨基噻吩-3-甲酸乙酯
• 中文别名: 2-氨基噻吩-3-羧酸乙酯
• 英文名称: ethyl 2-aminothiophene-3-carboxylate
• 英文别名: 2-aminothiophene-3-carboxylic acid ethyl ester；ethyl 2-amino-3-thiophenecarboxylate
• CAS: 31891-06-2
• 化学式: C₇H₉NO₂S
• mdl: MFCD01566303
• 分子量: 171.22
• InChiKey: MKJQYFVTEPGXIE-UHFFFAOYSA-N

物化性质

• 熔点：
  42 °C
• 沸点：
  273.6±20.0 °C(Predicted)
• 密度：
  1.262±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿、二氯甲烷

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.285
• 拓扑面积：
  80.6
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S37,S60
• 危险类别码：
  R36/37/38
• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Ethyl 2-aminothiophene-3-carboxylate
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
Ethyl 2-aminothiophene-3-carboxylate
Ingredient name:
CAS number: 31891-06-2

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C7H9NO2S
Molecular weight: 171.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

概述

2-氨基3-噻吩甲酸乙酯是噻吩的一类重要衍生物，α-噻吩衍生物广泛应用于合成医药、农药、染料、化学试剂和高分子助剂等。

用途

2-氨基3-噻吩甲酸乙酯可用于噻吩并嘧啶酮衍生物的合成与生物活性研究。

反应信息

• 作为反应物：
  描述：

  2-氨基噻吩-3-甲酸乙酯 在 甲酸 、 乙酸酐 作用下， 以 二氧化碳 为溶剂， 生成 乙基2-甲酰氨基-3-噻吩羧酸酯
  参考文献：
  名称：

  Fungicides

  摘要：

  该发明提供了一种用于对抗真菌的化合物的使用，其一般式为（I），其中R1为氢、羟基、酰基、酰氧基、可选择取代的氨基、Ra、Ra3Si、RaS或RaO，其中Ra为可选择取代的烷基、可选择取代的烯基、可选择取代的炔基、可选择取代的环烷基、可选择取代的环烯基、可选择取代的芳基或可选择取代的杂环基；R2具有与Ra相同的含义或可以是氢；Z为氧或硫，M为噻吩环，R3和R4，可能相同也可能不同，具有与Ra相同的含义或可以是可选择取代的氨基、氢、卤素、氰基、硝基或基团ORc或S(O)mRc，其中Rc具有与Ra相同的含义或为氢或酰基，m为0、1或2；或者R3和R4与它们连接的原子一起形成可选择取代的碳环或杂环；以及其中R1为氢的异构体的化合物。

  公开号：

  US06432964B1
• 作为产物：
  描述：

  1,4-dithiane-2,5-dithiol 、 氰乙酸乙酯 在 吗啉 、 sulfur 、 三乙胺 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 以71%的产率得到2-氨基噻吩-3-甲酸乙酯
  参考文献：
  名称：

  Thieno[3,2-c]pyran-4-one based novel small molecules: Their synthesis, crystal structure analysis and in vitro evaluation as potential anticancer agents

  摘要：

  Novel thieno[3,2-c]pyran-4-one based small molecules were designed as potential anticancer agents. Expeditious synthesis of these compounds was carried out via a multi-step sequence consisting of few steps such as Gewald reaction, Sandmeyer type iodination, Sonogashira type coupling followed by iodocyclization and then Pd-mediated various C-C bond forming reactions. The overall strategy involved the construction of thiophene ring followed by the fused pyranone moiety and then functionalization at C-7 position of the resultant thieno[3,2-c]pyran-4-one framework. Some of the compounds synthesized showed selective growth inhibition of cancer cells in vitro among which two compounds for example, 5d and 6c showed IC50 values in the range of 2.0-2.5 mu M. The crystal structure analysis of an active compound along with hydrogen bonding patterns and molecular arrangement present within the molecule is described. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.04.109

文献信息

• A Thieno[2,3-<i>d</i>]pyrimidine Scaffold Is a Novel Negative Allosteric Modulator of the Dopamine D₂ Receptor
  作者：Tim J. Fyfe、Barbara Zarzycka、Herman D. Lim、Barrie Kellam、Shailesh N. Mistry、Vsevolod Katrich、Peter J. Scammells、J. Robert Lane、Ben Capuano

  DOI：10.1021/acs.jmedchem.7b01565

  日期：2019.1.10

  Recently, a novel negative allosteric modulator (NAM) of the D2-like dopamine receptors 1 was identified through virtual ligand screening. This ligand comprises a thieno[2,3-d]pyrimidine scaffold that does not feature in known dopaminergic ligands. Herein, we provide pharmacological validation of an allosteric mode of action for 1, revealing that it is a NAM of dopamine efficacy and identify the structural

  最近，通过虚拟配体筛选鉴定了D 2样多巴胺受体1的新型负变构调节剂（NAM）。该配体包含在已知的多巴胺能配体中不具有的噻吩并[2,3- d ]嘧啶骨架。在此，我们提供了针对1的变构作用模式的药理学验证，表明这是多巴胺功效的NAM，并确定了这种变构的结构决定因素。我们发现关键的结构部分对于功能亲和力和负的协同作用很重要，而硫代嘧啶在5和6位的功能化导致类似物具有不同的协同作用谱。连续的化合物迭代产生了在功能亲和力方面表现出10倍改善的类似物，以及与多巴胺亲和力和功效增强的负协同性。此外，我们的研究揭示了一个片段样的核心，该核心保持了较低的μM亲和力和强大的负协同作用，并显着提高了配体效率。
• NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS
  申请人：Carroll William A.

  公开号：US20090018114A1

  公开（公告）日：2009-01-15

  The present application relates to cannabinoid receptor ligands containing compounds of formula (I) wherein A, R 1 , R 2 , and R 3 are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

  本申请涉及含有式(I)化合物的大麻素受体配体，其中A、R1、R2和R3如规范中所定义。本申请还涉及包含这种化合物的组合物，以及使用这种化合物和组合物治疗疾病和疾病的方法。
• [EN] COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS<br/>[FR] AGENTS PHARMACEUTIQUES EN COMBINAISON EN TANT QU'INHIBITEURS DE RSV
  申请人：ENANTA PHARM INC

  公开号：WO2019067864A1

  公开（公告）日：2019-04-04

  The present invention relates to pharmaceutical agents administered to a subject either in combination or in series for the treatment of a Respiratory Syncytial Virus (RSV) infection, wherein treatment comprises administering a compound effective to inhibit the function of the RSV and an additional compound or combinations of compounds having anti-RSV activity.

  本发明涉及用于治疗呼吸道合胞病毒（RSV）感染的药物剂，该药物剂可以单独或连续给予受试者，治疗包括给予一种有效抑制RSV功能的化合物以及具有抗RSV活性的另一种化合物或化合物组合。
• Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
  申请人：F. HOFFMANN-LA ROCHE LTD

  公开号：US20130102600A1

  公开（公告）日：2013-04-25

  The present invention relates to a compound having the general formula I, optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which is useful in treating, ameliorating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.

  本发明涉及一种具有通式I的化合物，可选地以药物可接受的盐、溶剂化物、多晶型、前药、互变异构体、外消旋体、对映体、非对映体或其混合物的形式，该化合物在治疗、改善或预防病毒性疾病方面有用。此外，还公开了特定的组合疗法。
• Computer-aided identification, synthesis and evaluation of substituted thienopyrimidines as novel inhibitors of HCV replication
  作者：Marcella Bassetto、Pieter Leyssen、Johan Neyts、Mark M. Yerukhimovich、David N. Frick、Andrea Brancale

  DOI：10.1016/j.ejmech.2016.07.035

  日期：2016.11

  technique was applied to the study of the HCV NS3 helicase, with the aim to find novel inhibitors of the HCV replication. A library of approximately 450000 commercially available compounds was analysed in silico and 21 structures were selected for biological evaluation in the HCV replicon assay. One hit characterized by a substituted thieno-pyrimidine scaffold was found to inhibit the viral replication with

  基于结构的虚拟筛选技术已应用于HCV NS3解旋酶的研究，目的是寻找HCV复制的新型抑制剂。在计算机上分析了大约450000种可商购化合物的文库，并选择了21种结构用于HCV复制子测定的生物学评估。发现一个以取代的噻吩并嘧啶骨架为特征的命中物以亚微摩尔范围的EC 50值和良好的选择性指数抑制病毒复制。设计并合成了不同系列的新型噻吩并嘧啶衍生物。几个新结构显示出在低或亚微摩尔范围内的抗病毒活性。